Latest News and Press Releases
Want to stay updated on the latest news?
Featured Releases
-
WASHINGTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The Bezos Earth Fund today announced $24.5 million in grants to help park rangers, coastal communities, and local organizations protect key marine areas...
Read More -
KALMAR CORPORATION, PRESS RELEASE, 9 DECEMBER 2025 AT 10.00 (EET) Kalmar joins forces with Kempower and SINEXCEL to accelerate the green transition in material-handling and logistics Kalmar is...
Read More
-
WASHINGTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The Bezos Earth Fund today announced $24.5 million in grants to help park rangers, coastal communities, and local organizations protect key marine areas...
-
SUSE and evroc Announce Strategic Partnership to Deliver Sovereign European Cloud Solutions
-
LUXEMBOURG et STOCKHOLM, 09 déc. 2025 (GLOBE NEWSWIRE) -- evroc, le cloud européen et SUSE, leader mondial des solutions open source d'entreprise, officialisent aujourd'hui un partenariat...
-
Opdateret prospekt for Værdipapirfonden BankInvest offentliggøres dags dato. Der er foretaget følgende opdateringer i prospektet: Justering af benchmark for afdelingerne, Optima 10 KLOptima 10 Akk....
-
KALMAR CORPORATION, PRESS RELEASE, 9 DECEMBER 2025 AT 10.00 (EET) Kalmar joins forces with Kempower and SINEXCEL to accelerate the green transition in material-handling and logistics Kalmar is...
-
London, UK – 9th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
-
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
-
Relation announces further $26 million investment
-
Aspocomp Group Plc, Management’s transaction, December 9, 2025, at 9:35 a.m. Finnish timeAspocomp Group Oyj - Managers' Transactions____________________________________________Person subject to the...
-
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3)Of the 6...